Pharmacy World & Science

, Volume 32, Issue 4, pp 503–511 | Cite as

Patterns of clozapine prescribing in a mental health service in New Zealand

  • Jeff HarrisonEmail author
  • Minna Janlöv
  • Amanda J. Wheeler
Research Article


Objective To describe clozapine prescribing in a mental health service in Auckland, New Zealand and compare it with national and international treatment guidelines. Setting A large public mental health service for adults in Auckland, New Zealand. Method A retrospective cross-sectional study of all adult outpatients and stable inpatients being treated with clozapine on 31st March 2007 in one mental health service in Auckland, New Zealand. Data on patient characteristics, diagnosis, duration of illness, number of hospitalisations, legal status relating to their treatment, living situation, marital status and occupational activity were recorded from case notes. Data collected on clozapine included date of initiation, dose and duration of treatment. Prior antipsychotic use and information on all other psychotropic drugs prescribed was also collected. Data were entered into a custom-designed Microsoft Access database and analysed using SPSSv15.0. Main outcome measures Clozapine prescribing patterns and concordance with best practice recommendations for clozapine use. Results 402 adult mental health outpatients and stable inpatients were eligible for inclusion. The mean daily dose of clozapine was 383 (SD 166) mg. For those first presenting after universal government funding, the mean time between presentation and initiation of clozapine, was 2.8 (SD 1.9) years, compared to 5.7 (SD 3.3) years prior to funding. Of those presenting after universal government funding, approximately two-thirds (69.0%) had ≤2 trials with other antipsychotics prior to commencing clozapine; of whom the majority (62.0%) received only second-generation antipsychotics (SGA). Both the number of antipsychotic agents trialled and the time to clozapine initiation has fallen since government subsidy was introduced in 1999. Based on a analysis of annualised hospitalization rates, it appears that shortening the delay to receiving clozapine leads to fewer hospitalisations in this treatment-resistant population, although this did not achieve statistical significance in our study. Conclusions Contemporary management of patients with treatment resistant schizophrenia in New Zealand is broadly in line with national and international best practice guidelines. There is some evidence, based on hospitalisation rates, to support the assertion that shorter delays in accessing clozapine leads to better outcomes. This needs further evaluation using measures of clinical outcome including objective measures of functioning.


Clinical audit Clozapine Guidelines New Zealand Prescribing Schizophrenia 



We would like to thank the mental health services and staff of the District Health Board mental health services.


This study was supported, in part, by funding from the New Zealand Pharmacy Education and Research Foundation and Uppsala University, Sweden. The investigators’ time was supported by The University of Auckland and the District Health Board.

Conflicts of interest



  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders fourth edition. Washington DC: American Psychiatric Association; 1994.Google Scholar
  2. 2.
    American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Washington DC: American Psychiatric Association; 2004.Google Scholar
  3. 3.
    Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Schizophrenia and Related Disorders. Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust NZ J Psychiatry. 2005;39(1–2):1–30.Google Scholar
  4. 4.
    National Collaborating Centre for Mental Health. Schizophrenia: core interventions in the treatment of schizophrenia in primary and secondary care. Clinical guideline 1. London: National Institute for Clinical Excellence; 2002.Google Scholar
  5. 5.
    Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.CrossRefPubMedGoogle Scholar
  6. 6.
    Hiltgen S, Mantelet S, Pinabel F, Enjaume F. Retrospective study of clozapine use in Ile-de-France. [Published in French as Étude rétrospective sur l’utilisation de la clozapine en Île-de-France] Encephale. 2006;32(5 Pt 1):688–96.Google Scholar
  7. 7.
    Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–96.PubMedGoogle Scholar
  8. 8.
    Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry. 2001;58(10):965–72.CrossRefPubMedGoogle Scholar
  9. 9.
    Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32(4):715–23.CrossRefPubMedGoogle Scholar
  10. 10.
    McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600–10.CrossRefPubMedGoogle Scholar
  11. 11.
    Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66(9):1116–21.CrossRefPubMedGoogle Scholar
  12. 12.
    Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull. 1991;17(2):247–61.PubMedGoogle Scholar
  13. 13.
    Novartis New Zealand Ltd. CLOZARIL® Data Sheet. Wellington, New Zealand: Medsafe (New Zealand Medicines and Medical Devices Safety Authority); 2009 [updated 2009 June 2009; cited 14/12/2009].
  14. 14.
    Douglas Pharmaceuticals Ltd. CLOPINE® Data Sheet. Wellington, New Zealand.: Medsafe (New Zealand Medicines and Medical Devices Safety Authority); 2009 [updated 2009 December 2008; cited 14/12/2009].
  15. 15.
    Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S, et al. Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch Gen Psychiatry. 2004;61(2):143–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry. 2005;187(3):248–55.CrossRefPubMedGoogle Scholar
  17. 17.
    National Institute for Clinical Excellence (NICE) Guidelines in the UK. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care National Institute for Clinical Excellence (NICE) guidelines in the UK. 2002. p. 1–264.Google Scholar
  18. 18.
    Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry. 2005;50(13):7S–57S.Google Scholar
  19. 19.
    Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. J Clin Psychiatry. 2003;64(Suppl 12):2–97.Google Scholar
  20. 20.
    Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004;30(2):193–217.PubMedGoogle Scholar
  21. 21.
    Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65(4):500–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Walker RA, Martin S. Demographic profile for Waitemata District health board: an analysis of 2006 census. Auckland: Watemata District Health Board; 2007.Google Scholar
  23. 23.
    Bailey D. A users guide to the Mental Health (Compulsory Assessment and Treatment) Act. Wellington: Department of Health; 1992.Google Scholar
  24. 24.
    Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988;45(1):79–91.PubMedGoogle Scholar
  25. 25.
    Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry. 2004;65(10):1377–88.CrossRefPubMedGoogle Scholar
  26. 26.
    Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Clinical correlates of clozapine prescription for schizophrenia in China. Hum Psychopharmacol. 2007;22(1):17–25.CrossRefPubMedGoogle Scholar
  27. 27.
    Ren XS, Kazis LE, Lee AF, Hamed A. Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. J Clin Pharm Therapeut. 2002;27:441–51.CrossRefGoogle Scholar
  28. 28.
    Wheeler A. Sociodemographic, functional and clinical correlates in outpatients with schizophrenia: comparison with affective disorders. Aust N Z J Psychiatry. 2007;41(10):809–18.CrossRefPubMedGoogle Scholar
  29. 29.
    Dickey B, Normand SL, Weiss RD, Drake RE, Azeni H. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv. 2002;53(7):861–7.Google Scholar
  30. 30.
    Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatry Scand. 2007;116(5):317–33.CrossRefPubMedGoogle Scholar
  31. 31.
    Sokal J, Messias E, Dickerson FB, Kreyenbuhl J, Brown CH, Goldberg RW, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis. 2004;192(6):421–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003;64(1):30–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Broekman WJ, de Groot IW, van Harten PN. Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics––a European study. Pharm World Sci. 2007;29:126–1230.CrossRefGoogle Scholar
  34. 34.
    McKean A, Vella-Brincat J, Begg E. Prescribing and monitoring clozapine in Christchurch. Aust Psychiatry. 2008;16(4):263–7.CrossRefGoogle Scholar
  35. 35.
    Conley RR, Kelly DL, Lambert TJ, Love RC. Comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatr Serv. 2005;56(3):320–3.Google Scholar
  36. 36.
    Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol. 2007;27(4):369–73.CrossRefPubMedGoogle Scholar
  37. 37.
    Kerwin R. When should clozapine be initiated in schizophrenia? Some arguments for and against earlier use of clozapine. CNS Drugs. 2007;21(4):267–78.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Jeff Harrison
    • 1
    • 4
    Email author
  • Minna Janlöv
    • 2
  • Amanda J. Wheeler
    • 3
    • 4
  1. 1.Medicines Management Research Group, School of Pharmacy, Faculty of Medical and Health SciencesThe University of AucklandAucklandNew Zealand
  2. 2.Faculty of PharmacyUppsala UniversityUppsalaSweden
  3. 3.School of PharmacyThe University of AucklandAucklandNew Zealand
  4. 4.Waitemata District Health BoardAucklandNew Zealand

Personalised recommendations